天津力生制药股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2026-009 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会未涉及变更以往股东会已通过的决议。 3.本次股东会采取现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间 （1）现场会议：2026年2月2日（星期一）下午3:30开始 （2）网络投票：2026年2月2日（星期一） 其中通过深圳证券交易所交易系统进行网络投票的具体时间为2026年2月2日上午 9:15—9:25,9:30—11:30和13:00—15:00；通过深圳证券交易所互联网投票系统进行网络 投票的具体时间为2026年2月2日9:15～15:00期间的任意时间。 （二）会议出席情况 | 分类 | 人数 | 代表股数（股） | 占公司有表决权股份总数的比例（%） | | --- | --- | --- | --- | | 1.总体出席情况 | 145 | 140,648 ...

天津力生制药股份有限公司 董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于近日收到渤海证券 股份有限公司（以下简称"渤海证券"）出具的《关于变更力生制药IPO项目持续督导保 荐代表人的通知》，具体情况如下： 渤海证券为天津力生制药股份有限公司IPO项目持续督导保荐机构，因募集资金尚 未使用完毕，渤海证券仍就剩余募集资金的使用情况继续履行持续督导责任。 由于原指派的保荐代表人张运发先生正常办理退休，不再担任公司持续督导的保荐 代表人，为保证持续督导工作的有序进行，渤海证券决定指派保荐代表人张化先生接替 其持续督导工作，履行保荐职责。本次变更后，天津力生制药股份有限公司IPO项目持 续督导的保荐代表人为方万磊先生和张化先生。 公司董事会对张运发先生在担任保荐代表人期间所做的工作表示衷心感谢！ 特此公告。 证券代码：002393 证券简称：力生制药 公告编号：2026-008 天津力生制药股份有限公司 关于变更持续督导保荐代表人的公告 2026 年 01 月 31 日 附张化先生简历： 张化先生，保荐 ...

Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

Group 1 - The company, Tianjin Lisheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its drug Aminophylline Tablets (0.1g) to pass the consistency evaluation of quality and efficacy for generic drugs [2] - The drug is classified as a chemical drug and is produced by Tianjin Lisheng Pharmaceutical Co., Ltd. The original drug approval number is Guoyao Zhunzi H12020118 [2] - Aminophylline Tablets are indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and can also be used for asthma caused by cardiogenic pulmonary edema [3] Group 2 - The approval of the drug enhances its market competitiveness for the company [4] - The sales performance of pharmaceutical products may be influenced by changes in the market environment, leading to significant uncertainty [4]

Core Viewpoint - Recently, Tianjin Lifesun Pharmaceutical Co., Ltd. received a notification from the National Medical Products Administration regarding the approval of the supplementary application for Aminophylline Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved specification for the drug is 0.1g, calculated based on C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O [1]

Core Viewpoint - Lisheng Pharmaceutical has received approval from the National Medical Products Administration for its 0.1g specification of Aminophylline tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The approval notification pertains to Aminophylline tablets, which are indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The drug is also applicable for asthma caused by cardiogenic pulmonary edema [1]

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

证券代码：002393 证券简称：力生制药 公告编号：2026-007 天津力生制药股份有限公司 关于药品氨茶碱片通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"本公司"）收到国家药品监督管理局 颁发的关于氨茶碱片（以下简称"该药品"）0.1g（按 C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O 计）规 格的《药品补充申请批准通知书》（批件号：2026B00421），该药品通过仿制药质量 和疗效一致性评价。 二、该药品的基本情况 规格：0.1g（按C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O计） 注册分类：化学药品 药品生产企业：天津力生制药股份有限公司 原药品批准文号：国药准字H12020118 申请内容：仿制药质量和疗效一致性评价 受理号：CYHB2550123 审批结论：通过仿制药质量和疗效一致性评价。 三、该药品的相关信息 氨茶碱片适应症： 药品名称：氨茶碱片 剂型：片剂 公司该药品通过仿制药质量和疗效一致性评价，有利于提升该药品市场竞争力。由 于医药产品的行业特点，各类产品 ...

力生制药公告称，公司收到国家药监局颁发的氨茶碱片0.1g规格的《药品补充申请批准通知书》，该药 品通过仿制药质量和疗效一致性评价。此药适用于缓解支气管哮喘等喘息症状，也可用于心源性肺水肿 引起的哮喘。公司表示，该药品通过评价有利于提升市场竞争力，但医药产品销售受市场环境等因素影 响，具有不确定性，提醒投资者注意风险。 ...

Core Viewpoint - The company emphasizes its commitment to fulfilling social responsibilities sustainably while providing quality pharmaceuticals and health services to more patients in alignment with national policies and local needs [1]. Group 1 - The company acknowledges its role as a listed entity in meeting social responsibilities [1]. - Future efforts will focus on integrating national policy directions with local actual needs [1]. - The aim is to ensure that quality medicines and professional health services benefit a larger patient base [1].